AcelRx Announces FDA Acceptance of NDA for DSUVIA

Treatment for Pain AcelRx Announces FDA Acceptance of NDA for DSUVIA Print this page REDWOOD CITY, Calif., May 24, 2018 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the […]

Teva Confirms September PDUFA Date for Fremanezumab

fremanezumab Treatment for Migraine Prophylaxis Teva Confirms September PDUFA Date for Fremanezumab Print this page JERUSALEM–(BUSINESS WIRE)–May 23, 2018– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that […]